These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 39145393)

  • 1. Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors.
    Travers RJ; Stepanian A; Jaffe IZ
    Arterioscler Thromb Vasc Biol; 2024 Oct; 44(10):2143-2153. PubMed ID: 39145393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Toxic Effects of Targeted Cancer Therapies.
    Moslehi JJ
    N Engl J Med; 2016 Oct; 375(15):1457-1467. PubMed ID: 27732808
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.
    Gustafson D; Fish JE; Lipton JH; Aghel N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):20-30. PubMed ID: 32078113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond.
    Di Lisi D; Madonna R; Zito C; Bronte E; Badalamenti G; Parrella P; Monte I; Tocchetti CG; Russo A; Novo G
    Int J Cardiol; 2017 Jan; 227():11-17. PubMed ID: 27866063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors.
    Fleming MR; Xiao L; Jackson KD; Beckman JA; Barac A; Moslehi JJ
    Circ Res; 2021 Jun; 128(12):1973-1987. PubMed ID: 34110908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?
    Herrmann J
    Curr Oncol Rep; 2016 Jun; 18(6):33. PubMed ID: 27099141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management.
    Sundararajan S; Kumar A; Poongkunran M; Kannan A; Vogelzang NJ
    Future Oncol; 2016; 12(8):1067-80. PubMed ID: 26901457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardio-oncology: management of cardiovascular toxicity.
    Markman TM; Markman M
    F1000Res; 2019; 8():. PubMed ID: 30755794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms.
    Pantazi D; Tselepis AD
    Thromb Res; 2022 May; 213 Suppl 1():S95-S102. PubMed ID: 36210569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.
    Aghel N; Delgado DH; Lipton JH
    Vasc Health Risk Manag; 2017; 13():293-303. PubMed ID: 28831263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-stimulated VEGFR2 signaling is regulated by co-ordinated trafficking and proteolysis.
    Bruns AF; Herbert SP; Odell AF; Jopling HM; Hooper NM; Zachary IC; Walker JH; Ponnambalam S
    Traffic; 2010 Jan; 11(1):161-74. PubMed ID: 19883397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury.
    Neves KB; Rios FJ; Jones R; Evans TRJ; Montezano AC; Touyz RM
    Cardiovasc Res; 2019 Apr; 115(5):978-988. PubMed ID: 30753341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms for vascular complications of targeted cancer therapies.
    Gopal S; Miller KB; Jaffe IZ
    Clin Sci (Lond); 2016 Oct; 130(20):1763-79. PubMed ID: 27612952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-199a-3p and MicroRNA-199a-5p Take Part to a Redundant Network of Regulation of the NOS (NO Synthase)/NO Pathway in the Endothelium.
    Joris V; Gomez EL; Menchi L; Lobysheva I; Di Mauro V; Esfahani H; Condorelli G; Balligand JL; Catalucci D; Dessy C
    Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2345-2357. PubMed ID: 29976767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unveiling the Cardiotoxicity Conundrum: Navigating the Seas of Tyrosine Kinase Inhibitor Therapies.
    Ekram J; Rathore A; Avila C; Hussein R; Alomar M
    Cancer Control; 2024; 31():10732748241285755. PubMed ID: 39318033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular toxicity of biologic agents for cancer therapy.
    Bhave M; Akhter N; Rosen ST
    Oncology (Williston Park); 2014 Jun; 28(6):482-90. PubMed ID: 25134321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
    Amin DN; Bielenberg DR; Lifshits E; Heymach JV; Klagsbrun M
    Microvasc Res; 2008 May; 76(1):15-22. PubMed ID: 18440031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular toxicity of new agents.
    Maitland ML
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):657-9. PubMed ID: 18827788
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
    Upshaw JN
    Curr Oncol Rep; 2020 Jun; 22(7):72. PubMed ID: 32564220
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.